Company profile

Ticker
ABEO
Exchange
CEO
Joao Siffert
Employees
Incorporated
Location
Fiscal year end
Former names
Access Pharmaceuticals Inc, Chemex Pharmaceuticals Inc, Plasmatech Biopharmaceuticals Inc
SEC CIK
IRS number
830221517

ABEO stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

10 Aug 20
11 Aug 20
31 Dec 20

News

Company financial data Financial data

Quarter (USD) Jun 20 Mar 20 Dec 19 Sep 19
Revenue
Net income -13.01M -48.16M -16.43M -17.37M
Diluted EPS -0.14 -0.52 -0.3 -0.35
Operating income -12.48M -48.21M -16.41M -17.65M
Net change in cash -25.61M -89.1M 81.34M 5.31M
Cash on hand 14.54M 40.16M 129.26M 47.92M
Cost of revenue
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 3M 837K 889K
Net income -76.28M -56.67M -27.32M -21.87M
Diluted EPS -1.51 -1.19 -0.66 -0.64
Net profit margin -1890% -3264% -2460%
Operating income -77.09M -58.17M -27.84M -23.88M
Net change in cash 110.51M -119M 68.61M 29M
Cash on hand 129.26M 18.75M 137.75M 69.14M
Cost of revenue

Financial data from company earnings reports

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
17 Jun 20 Migausky George V Common Stock Grant Aquire A No 0 37,954 0 37,954
17 Jun 20 Migausky George V Stock Option Common Stock Grant Aquire A No 3.03 45,566 138.06K 45,566
17 Jun 20 Mann Paul Elliot Common Stock Grant Aquire A No 0 37,954 0 37,954
17 Jun 20 Mann Paul Elliot Stock Option Common Stock Grant Aquire A No 3.03 45,566 138.06K 45,566
20 May 20 Buono Stefano Common Stock Grant Aquire A No 0 17,969 0 287,969
20 May 20 Buono Stefano Stock Option Common Stock Grant Aquire A No 3.2 21,518 68.86K 21,518
53.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 87 96 -9.4%
Opened positions 12 26 -53.8%
Closed positions 21 19 +10.5%
Increased positions 31 35 -11.4%
Reduced positions 23 11 +109.1%
13F shares
Current Prev Q Change
Total value 127.47M 205.95M -38.1%
Total shares 44.48M 55.01M -19.1%
Total puts 78.4K 91.5K -14.3%
Total calls 77.6K 415.8K -81.3%
Total put/call ratio 1.0 0.2 +359.1%
Largest owners
Shares Value Change
Great Point Partners 7.21M $15.15M 0.0%
Adage Capital Partners GP, L.L.C. 5.5M $11.55M +10.0%
Wellington Management 5.44M $11.43M -15.9%
BLK BlackRock 3.67M $7.7M +47.4%
Vanguard 2.92M $6.14M +10.7%
Knoll Capital Management 2.86M $6.01M 0.0%
Point72 Asset Management 1.68M $3.52M -1.5%
Baker Bros. Advisors 1.59M $3.34M -30.5%
Perceptive Advisors 1.5M $3.06M 0.0%
Citadel Advisors 1.37M $2.87M +241.1%
Largest transactions
Shares Bought/sold Change
CVI 0 -5.23M EXIT
Farallon Capital Management 0 -2M EXIT
Millennium Management 1.2M -1.89M -61.2%
Schonfeld Strategic Advisors 0 -1.46M EXIT
Avidity Partners Management 0 -1.33M EXIT
BLK BlackRock 3.67M +1.18M +47.4%
Wellington Management 5.44M -1.03M -15.9%
Citadel Advisors 1.37M +965.08K +241.1%
Sphera Funds Management 0 -720.47K EXIT
Baker Bros. Advisors 1.59M -697.55K -30.5%

Financial report summary

?
Management Discussion
  • Foundation revenues relate to a collaborative agreement between nine Sanfilippo foundations and us to provide up to approximately $13.9 million of grants to us in installments for the advancement of our clinical stage gene therapies for MPS IIIA and MPS IIIB, subject to the achievement of certain milestones. We have received $5.7 million of such grants cumulatively as of December 31, 2019. The cash received upfront from the foundations is deferred on the consolidated balance sheet until the costs of the activities as outlined in the manufacturing and clinical work plan are incurred by installment as outlined in the agreement with the foundations. As a result, we record foundation revenues to match the costs of the activities by installment performed under the collaborative agreement. Our foundation revenue was $0 for the year ended December 31, 2019, as compared to $2.8 million for the same period of 2018. We did not record foundation revenue in 2019 since we have previously recognized revenue up to the amount of cash received to date by installment performed.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: Absent, Additionally, administered, Aid, alternative, American, analyzing, authorized, Brian, Carolina, Carr, certification, certify, Chapel, civil, claim, consume, controversy, counterclaim, coverage, criminal, criteria, deferral, detail, disbursed, document, duly, Edward, embedded, evolve, evolving, exhibit, faith, forgiven, formatted, found, gradually, half, harm, hereof, Hill, inaccurate, Index, ineligible, Inline, Interactive, interpretation, irrespective, language, loan, local, media, mortgage, nil, North, ongoing, owed, Page, panel, Paycheck, payroll, Pereira, portion, PPP, prevail, proposed, qualification, Quarterly, reinstituting, Restated, Rule, satisfied, SBA, scalability, Siffert, Small, temporarily, thereunto, undersigned, unforgiven, VIITALTM, XBRL
Removed: Chairman, human, installment, recent, scale, Stanford